These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Discovery of alpha-aminoazaheterocycle-methylglyoxal adducts as a new class of high-affinity inhibitors of cystic fibrosis transmembrane conductance regulator chloride channels. Routaboul C; Norez C; Melin P; Molina MC; Boucherle B; Bossard F; Noel S; Robert R; Gauthier C; Becq F; Décout JL J Pharmacol Exp Ther; 2007 Sep; 322(3):1023-35. PubMed ID: 17578899 [TBL] [Abstract][Full Text] [Related]
7. Oridonin: a small molecule inhibitor of cystic fibrosis transmembrane conductance regulator (CFTR) isolated from traditional Chinese medicine. Luan J; Zhang Y; Yang S; Wang X; Yu B; Yang H Fitoterapia; 2015 Jan; 100():88-94. PubMed ID: 25447156 [TBL] [Abstract][Full Text] [Related]
8. Bioelectric properties of chloride channels in human, pig, ferret, and mouse airway epithelia. Liu X; Luo M; Zhang L; Ding W; Yan Z; Engelhardt JF Am J Respir Cell Mol Biol; 2007 Mar; 36(3):313-23. PubMed ID: 17008635 [TBL] [Abstract][Full Text] [Related]
9. Recent Progress in the Discovery and Development of Small-Molecule Modulators of CFTR. Kym PR; Wang X; Pizzonero M; Van der Plas SE Prog Med Chem; 2018; 57(1):235-276. PubMed ID: 29680149 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors in polycystic kidney disease. Li H; Sheppard DN BioDrugs; 2009; 23(4):203-16. PubMed ID: 19697963 [TBL] [Abstract][Full Text] [Related]
11. Expression and function of Anoctamin 1/TMEM16A calcium-activated chloride channels in airways of in vivo mouse models for cystic fibrosis research. Hahn A; Salomon JJ; Leitz D; Feigenbutz D; Korsch L; Lisewski I; Schrimpf K; Millar-Büchner P; Mall MA; Frings S; Möhrlen F Pflugers Arch; 2018 Sep; 470(9):1335-1348. PubMed ID: 29860639 [TBL] [Abstract][Full Text] [Related]
12. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy. Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971 [TBL] [Abstract][Full Text] [Related]
13. On the discovery and development of CFTR chloride channel activators. Becq F Curr Pharm Des; 2006; 12(4):471-84. PubMed ID: 16472140 [TBL] [Abstract][Full Text] [Related]
14. Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients. Dray-Charier N; Paul A; Scoazec JY; Veissière D; Mergey M; Capeau J; Soubrane O; Housset C Hepatology; 1999 Jun; 29(6):1624-34. PubMed ID: 10347100 [TBL] [Abstract][Full Text] [Related]
15. Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. Chung WJ; Goeckeler-Fried JL; Havasi V; Chiang A; Rowe SM; Plyler ZE; Hong JS; Mazur M; Piazza GA; Keeton AB; White EL; Rasmussen L; Weissman AM; Denny RA; Brodsky JL; Sorscher EJ PLoS One; 2016; 11(10):e0163615. PubMed ID: 27732613 [TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator and the outwardly rectifying chloride channel: a relationship between two chloride channels expressed in epithelial cells. Hryciw DH; Guggino WB Clin Exp Pharmacol Physiol; 2000 Nov; 27(11):892-5. PubMed ID: 11071305 [TBL] [Abstract][Full Text] [Related]
17. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
18. A Homogeneous Cell-Based Halide-Sensitive Yellow Fluorescence Protein Assay to Identify Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Ion Channel. Smith E; Giuliano KA; Shumate J; Baillargeon P; McEwan B; Cullen MD; Miller JP; Drew L; Scampavia L; Spicer TP Assay Drug Dev Technol; 2017 Dec; 15(8):395-406. PubMed ID: 29172645 [TBL] [Abstract][Full Text] [Related]
19. Integration of small-molecule discovery in academic biomedical research. Ohlmeyer M; Zhou MM Mt Sinai J Med; 2010; 77(4):350-7. PubMed ID: 20687180 [TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]